Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tang

Showing results (471-480 of 556) with videos related to

Pageof 56
Sort By:
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|May 22, 2023
Mitigation of COVID-19 transmission in endoscopic and surgical aerosol-generating procedures: a narrative review of early-pandemic literatureV W S Chan, L Rahman, H H L Ng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervixA P Kudelka, T Levy, C F Verschraegen, et al.
Physical Review Letters|December 12, 2001
Energy dependence of nuclear transparency in C (p,2p) scatteringA Leksanov, J Alster, G Asryan, et al.
Physical Review Letters|February 7, 2003
n-p short-range correlations from (p,2p+n) measurementsA Tang, J W Watson, J Aclander, et al.
The Journal of Clinical Investigation|April 1, 2021
ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defectsHaiyan Qiu, Sebum Lee, Yulei Shang, et al.
The Journal of Clinical Investigation|February 11, 2014
ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defectsHaiyan Qiu, Sebum Lee, Yulei Shang, et al.
Neuron|June 21, 2016
Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral SclerosisSebum Lee, Yulei Shang, Stephanie A Redmond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 14, 2016
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapyM Moore, S Gill, T Asmis, et al.
The New England Journal of Medicine|May 4, 2017
Teprotumumab for Thyroid-Associated OphthalmopathyTerry J Smith, George J Kahaly, Daniel G Ezra, et al.
Nature Communications|July 1, 2021
RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric siteKatarzyna Z Haza, Heather L Martin, Ajinkya Rao, et al.
Pageof 56

Showing results (471-480 of 556) with videos related to

Sort By:
Pageof 56
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|May 22, 2023
Mitigation of COVID-19 transmission in endoscopic and surgical aerosol-generating procedures: a narrative review of early-pandemic literatureV W S Chan, L Rahman, H H L Ng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervixA P Kudelka, T Levy, C F Verschraegen, et al.
Physical Review Letters|December 12, 2001
Energy dependence of nuclear transparency in C (p,2p) scatteringA Leksanov, J Alster, G Asryan, et al.
Physical Review Letters|February 7, 2003
n-p short-range correlations from (p,2p+n) measurementsA Tang, J W Watson, J Aclander, et al.
The Journal of Clinical Investigation|April 1, 2021
ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defectsHaiyan Qiu, Sebum Lee, Yulei Shang, et al.
The Journal of Clinical Investigation|February 11, 2014
ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defectsHaiyan Qiu, Sebum Lee, Yulei Shang, et al.
Neuron|June 21, 2016
Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral SclerosisSebum Lee, Yulei Shang, Stephanie A Redmond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 14, 2016
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapyM Moore, S Gill, T Asmis, et al.
The New England Journal of Medicine|May 4, 2017
Teprotumumab for Thyroid-Associated OphthalmopathyTerry J Smith, George J Kahaly, Daniel G Ezra, et al.
Nature Communications|July 1, 2021
RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric siteKatarzyna Z Haza, Heather L Martin, Ajinkya Rao, et al.
Pageof 56